Octreotide vs Pasireotide
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Octreotide or Pasireotide?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Octreotide and Pasireotide?
Pasireotide binds somatostatin receptor subtypes 1, 2, 3, and 5 (broader than octreotide, which is SST2-preferring), making it effective in Cushing disease - but the SST5-mediated insulin suppression causes clinically significant hyperglycemia.
Evidence Comparison
Octreotide (Sandostatin): decades of Phase 3 data in acromegaly, carcinoid syndrome, and variceal bleeding; first-line guideline therapy. Pasireotide (Signifor): FDA approved for Cushing disease and acromegaly, but ~70% hyperglycemia rate in clinical trials limits its use to second-line. Octreotide has broader and more favorable evidence.
Evidence Context Favoring Octreotide
First-line acromegaly, carcinoid syndrome, or variceal bleeding management where octreotide is the guideline-supported choice.
Evidence Context Favoring Pasireotide
Cushing disease specifically, particularly when surgery has failed, accepting the ~70% hyperglycemia risk with appropriate glucose monitoring.
Side-by-Side Snapshot
| Evidence grade | Octreotide: Level A Pasireotide: Level A |
|---|---|
| Research status | Octreotide: FDA Approved Pasireotide: FDA Approved |
| Primary category | Octreotide: Growth Hormone Pasireotide: Growth Hormone |
| Cited studies | Octreotide: 3 Pasireotide: 3 |